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Abstract Palmitoylcarnitine is a well-known intermediate in 
mitochondrial fatty acid oxidation. Less known are its properties 
as a snrfactant, with a capacity to solubilize biological 
membranes imilar to that of many synthetic detergents used in 
the biochemical laboratory. Some of the physico-chemical 
properties of palmitoylcarnitine may help to explain the need 
for coenzyme A-carnitine-coenzyme A acyl exchange during 
mitochondrial fatty acid import. The amphiphilic character of 
palmitoylcarnitine may also explain its proposed involvement in 
the pathogenesis of myocardial ischemia. 
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1. Introduction and definitions 
air. The molecules at the interface may be quantitatively un- 
important, but they are the ones giving a surfactant i s char- 
acteristic property, i.e. the decrease in surface tension. Above 
the cmc, most of the molecules in the bulk of the solvent 
associate with eachother giving rise to micelles, and the fol- 
lowing equilibrium is established: 
micelles ~ monomers in solution ~ monomers at interface 
The net effect of adding a surfactant to a two-phase system 
is to increase the surface of contact between both phases, or 
interface. Adding soap to a recipient with water increases the 
surface of air-water contact hrough foam formation. In the 
digestive tract, bile salts increase the fat-water interface by 
giving rise to lipid-bile salt mixed micelles. In the lung alveoli, 
the complex mixture known as the 'lung surfactant' increases 
the tissue-air interface and thus prevents alveolar collapse. 
Palmitoylcarnitine is an important intermediate of fatty acyl 
degradation i  mitochondria, and it is recognized as such in 
any basic biochemistry textbook. However, its remarkable 
physico-chemical properties are not so widely known, 
although they may help to explain some aspects of fatty 
acid metabolism. In addition, there are recent data suggesting 
a role for palmitoylcarnitine in pathological processes. All 
these aspects are reviewed, and to some extent correlated, 
below. 
In our context, the term palmitoylcarnitine is used as an 
example of the variety of long-chain fatty acylcarnitines that 
occur in the mitochondrial degradation of fatty acids and 
among which the palmitoyl (IUPAC hexadecanoyl) derivative 
occurs frequently. 
Surface-active molecules, or surfactants, are those mole- 
cules that, when added to a solvent (in our case water or 
aqueous olution), cause a decrease in the surface tension at 
the air-solvent interface. Surfactants are amphipathic (amphi- 
philic) molecules, i.e. molecules having both a polar and a 
non-polar moiety. More specifically, surface-active molecules 
are soluble amphiphiles, i.e. giving rise to clear, stable solu- 
tions. (Not all amphiphiles are soluble, e.g. diacylglycerols, or
phospholipids.) The behavior of surfactants in solution is rel- 
atively complex. Below a certain concentration, the so-called 
critical micellar concentration (cmc), the individual molecules 
in the bulk of the solvent are in equilibrium with those at the 
air-water interface, the latter oriented with their polar moi- 
eties towards the water, and their non-polar parts towards the 
*Corresponding author. 
Abbreviations: CoA, coenzyme A; cmc, critical micellar concentra- 
tion; Re, effective surfactant/lipid molar ratio 
2. Palmitoylcarnitine as a surfaetant 
The surface-active properties of palmitoylcarnitine (Fig. 1) 
have been known for long. They have been independently 
described in the physico-chemical nd biological 'worlds' 
but, as is often the case, the integrated understanding of 
both groups of results has taken considerably onger. Among 
the physico-chemical studies, Yalkowsky and Zografi [1,2] de- 
scribed the critical micellar concentrations and other para- 
meters of various long-chain carnitine derivatives. In the fol- 
lowing decade, Pande [3] indicated the tendency of 
palmitoylcarnitine in solution to migrate to the air-water in- 
terface. In 1990, Stinson [4] demonstrated that palmitoylcar- 
nitine can exist in various phases (e.g. lamellar, hexagonal) in 
the presence of water, a typical property of amphiphiles and 
surfactants. More recently, Requero et al. [5] described the 
influence of electrolytes and other factors on the critical mi- 
cellar concentrations and other pertinent properties of acyl- 
carnitines. Finally, Requero et al. [6] have provided direct 
measurements, using a Langmuir-type balance, of the increase 
in surface pressure that occurs at the air-water interface when 
palmitoylcarnitine is injected in the bulk of the solvent. In 
addition, when the air-water interface is initially covered by 
a monomolecular layer of phospholipids (e.g. egg phospha- 
tidylcholine), injection of palmitoylcarnitine in the solvent is 
followed by penetration of the carnitine derivative into the 
phospholipid monolayer, a lateral stabilisation arising from 
the interaction between both lipids [6]. 
Detergents (or, more appropriately, surfactants) are com- 
monly used in biological experimentation for the breaking 
down and solubilization of membranes, to the point that, 
from the biological point of view, surfactants are empirically 
characterized by their ability to solubilize membranes, rather 
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than after their affinity for interfaces. Perhaps the earliest 
realization of palmitoylcarnitine as a surfactant, from the 
point of view of biochemical experimentation, can be attrib- 
uted to Schwartz and co-workers [7], who studied the effect of 
this amphiphile on the Na, K-ATPase and Ca-ATPase activ- 
ities from heart sarcolemma nd sarcoplasmic reticulum re- 
spectively. These authors correctly explained the concentra- 
tion-dependent effects of palmitoylcarnitine by assuming 
that this molecule acts 'as a naturally occurring detergent', 
and they invoked in support of their idea the physico-chemical 
studies by Yalkowsky and Zografi [1,2]. The abilities of var- 
ious long-chain acylcarnitines to destabilize and/or solubilize 
sonicated phosphatidylcholine liposomes and sarcoplasmic re- 
ticulum vesicles were explored in a systematic way by 
Haeyaert et al. [8]. 
The proposal by Lichtenberg [9,10] of the use of 'effective 
surfactant/lipid ratios' Re as parameters in solubilization stu- 
dies has been very useful in rationalising experimental results 
in this field. In calculating these effective ratios only the de- 
tergent molecules in the membrane phase are taken into ac- 
count, but not those in the bulk of the solvent (the amount at 
the air-water interface being negligible). Effective surfactant/ 
lipid ratios Re are independent from membrane concentration. 
Re SAT is the effective ratio at which the bilayer is detergent- 
saturated, so that solubilization starts; Re s°L is the effective 
ratio at which solubilization is completed. For reasons that 
are not fully understood at present, Re sAT and Re s°L have 
rather constant values of ,~ 1 and of ~ 2-3 respectively, for 
most if not all the biochemically used surfactants. Requero et 
al. [11] have characterized in detail the binding and solubiliza- 
tion of large unilamellar vesicles of phosphatidylcholine by
palmitoylcarnitine; they conclude that this amphiphile has 
the properties of the commonly used biochemical detergents. 
The critical micellar concentration of palmitoylcarnitine is in 
the 10 -5 M range under a variety of conditions, well below 
the corresponding values for detergents such as Triton X-100 
(3.7×10 -4 M), CHAPS (3.5×10 -3 M), or Hecameg 
(1.65× l0 -2 M) [5]. A low critical micellar concentration is 
generally indicative of extensive intermolecular hydrophobic 
interactions. In the presence of membranes, it should lead to a 
high degree of partition into the lipid phase, as is indeed the 
case for palmitoylcarnitine according to Requero et al. [11]. 
Their binding experiments indicate that when palmitoylcarni- 
tine is added to a liposome suspension, virtually all of the 
surfactant becomes membrane-bound, the concentration of 
free palmitoylcarnitine in water approaching the critical mi- 
cellar concentration. Also in agreement with the above, the 
membrane/water partition equilibrium constant K (34 mM -1) 
is much higher than those of, e.g. Triton X-100 (1.9 mM -1 
[12]) or Hecameg (0.08 mM -1 [13]). The Re sAT and Re sOL 
values for palmitoylcarnitine in egg phosphatidylcholine bi-
layers are respectively of 0.78 and 1.97 [11]. As was mentioned 
above, these values are similar to the corresponding ones for 
biochemically used surfactants, e.g. Triton X-100 (0.71 and 
3.0 [12]) or Hecameg (1.4 and 2.6 [13]). In summary, palmi- 
toylcarnitine is, from the physico-chemical point of view, a 
surfactant with solubilising properties equivalent to many nat- 
ural or synthetic detergents hat are commonly in use in bio- 
logical laboratories. 
It should be noted at this stage that, while being also an 
amphiphile, palmitoyl-CoA does not share the membrane lytic 
properties of palmitoylcarnitine. Palmitoyl-CoA inserts its hy- 
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Fig. 1. Chemical structures of long-chain fatty acyl compounds. 
(a) Palmitic (IUPAC hexadecanoic) acid. (b) Palmitoylcarnitine. 
(c) Palmitoyl-coenzyme A. 
drophobic moiety in the bilayer, but without producing mem- 
brane leakage or lysis [11,14]. The importance of this observa- 
tion will become obvious in the next section. 
The surfactant properties of long-chain acylcamitines have 
been observed in a variety of membranous systems. Palmitoyl- 
carnitine was shown to induce alterations in membrane fluid- 
ity of erythrocytes [15]. The observed enhancement of hydro- 
phobic drug absorption through epithelia in the presence of 
palmitoylcarnitine [16] can probably be ascribed to the mem- 
brane permeabilizing effect of the amphiphile at sublytic con- 
centrations [11]. Palmitoylcarnitine d creases the electrical re- 
sistance of phospholipid model membranes and, in rat liver 
mitochondria, it induces energy-dependent swelling of the mi- 
tochondrial matrix [17]. Both palmitoyl-CoA and palmitoyl- 
carnitine dissipate the transmembrane potential of rat heart 
mitochondria [18], the effects of the former being prevented by 
ruthenium red, cyclosporin A or Mg 2+. The fall of membrane 
potential induced by palmitoylcarnitine cannot be prevented 
by any of those agents, suggesting that only palmitoylcarni- 
tine is exerting its surfactant properties at the level of the 
membrane bilayer. Paradoxically, Piper et al. [45] have shown 
that long-chain acylcarnitines prevent osmotic lysis of red 
blood cells at low concentrations; imilar 'protective' ffects 
have been found for other surfactants at low concentrations in 
various cell and model membranes. Other examples of mem- 
brane activity of palmitoylcarnitine are related to pathological 
conditions, and will be discussed in the next sections. 
3. Palmitoylcarnitine in mitochondrial fatty acid import 
In the former section we have dealt with palmitoylcamitine 
as a molecule. Now we shall think of it as of a metabolite. It is 
well known that palmitoylcarnitine is an essential intermediate 
in fatty acid transport across the mitochondrial inner mem- 
brane. Mitochondrial 13-oxidation of long-chain fatty acids 
takes place in the matrix. Fatty acyl-CoAs are generated on 
the outer mitochondrial membrane and converted into fatty 
acylcarnitines (e.g. palmitoylcarnitine) by carnitine palmitoyl- 
transferase I, an enzyme located on the inner side of the outer 
mitochondrial membrane (Fig. 2). Palmitoyl-carnitine passes 
through a carnitine-acylcarnitine translocase to the inner part 
of the inner mitochondrial membrane, where a second coen- 
zyme exchange takes place, opposite to the former one: car- 
nitine palmitoyltransferase II converts fatty acylcarnitines into 
fatty acyl-CoAs, that can now undergo 13-oxidation in the 
mitochondrial matrix. More details on the carnitine palmi- 
toyltransferases may be found in [19,20]. Long-chain carnitine 
acyltransferases are also found in peroxisomes, and in endo- 
plasmic reticulum, that also exchange carnitine for coenzyme 
A and vice versa [20]. 
F.M. Go~i et al./FEBS Letters 390 (1996) 1-5 3 
The reasons by which this double coenzyme xchange ac- 
companies fatty acid membrane transport are unclear. The 
traditional explanation was that carnitine esters would tra- 
verse the bilayer more easily than the corresponding deriva- 
tives of the bulky coenzyme A (Fig. 1). This hypothesis was 
proposed well before the discovery of the carnitine-acylcarni- 
fine translocase [21,22] but has found its way even to present- 
day biochemistry textbooks. In fact, fatty acylcarnitines 
hardly if at all diffuse ('flip-flop') across phospholipid bilayers 
[11,23,26,44]. It is true that, for a relatively simple transloca- 
tor (Mr 33 000, [24]) acylcarnitines may be easier to deal with 
than acyl-CoAs, but this explanation does not appear very 
satisfactory, particularly when we know that macromolecules 
much larger than acyl-CoAs are being actually imported into 
the mitochondria. One possible difficulty offered by coenzyme 
A, but not by carnitine derivatives, is the establishment of
attractive interactions between the long and complex coen- 
zyrne A moiety and the membrane surface, that would hinder 
the translocation. Recent infrared spectroscopic evidence sug- 
gests that a significant interaction may occur between some 
coenzyme A group and the carbonyl groups of the phospho- 
lipid [14]. Such interactions would constitute another factor 
favoring the coenzyme A-carnitine xchange. 
Another view on the need for a double coenzyme xchange 
at the mitochondrial membrane level is that carnitine would 
be used to buffer the availability of coenzyme A in the matrix 
Table 1 
Concentrations of carnitine, coenzyme A, and their derivatives, in various tissues, cells and subcellular f actions 
Source Metabolite Concentration Reference 
1 Human red blood cells Free camitine 12-29 gM [38] 
Acetylcarnitine 13 30 HM [38] 
2 Human muscle Total carnitine 4 mM [38] 
3 Human mononuclear phagocytes Free camitine 0.20 gM ~ [39] 
Fatty acylcarnitine 0.40 gM ~ [39] 
Total carnitine 8 gM ~ [39] 
4a Rat heart (non-perfused) 
Cytosol 
Mitochondrial matrix 
4b Rat heart (control, perfused) 
Cytosol 
Mitochondrial matrix 




Rat heart (control, perfused) 
Cytosol 
Mitochondrial matrix 
5 Rat plasma 




Rat skeletal muscle 
Acid-soluble camitine b 2.5 mM [40] 
Fatty acylcarnitine 0.025 mM [40] 
Total carnitine 2.65 mM [40] 
Acid-soluble carnitine 2.03 mM [40] 
Fatty acylcarnitine 0 [40] 
Total carnitine 2.03 mM [40] 
Acid-soluble carnitine 2.18 mM [40] 
Fatty acycarnitine 0.38 mM [40] 
Total carnitine 2.56 mM [40] 
Acid-soluble carnitine 1.62 mM [40] 
Fatty acylcarnitine 0.22 mM [40] 
Total carnitine 1.84 mM [40] 
Acid-soluble carnitine 0.43 mM [40] 
Fatty acylcarnitine 1.95 mM [40] 
Total camitine 2.37 mM [40] 
Acid-soluble carnitine 2.93 mM [40] 
Fatty acylcarnitine 1.88 mM [40] 
Total carnitine 4.81 mM [40] 
Total coenzyme A 0.014 mM [40] 
Fatty acyl-CoA 0.52 mM [40] 
Total coenzyme A 2.10 mM [40] 
Fatty acylcarnitine 3-18 gM [41] 
Free camitine 28 laM a [42] 
Fatty acylcarnitine 1.7 txM ~ [42] 
Total carnitine 33.5 i.tM a [42] 
Free carnitine 183.7 gM a [42] 
Fatty acylcarnitine 24.2 I.tM ~ [42] 
Total carnitine 251.9 gM a [42] 
Total coenzyme A 136.4 laM a [42] 
Free carnitine 630.3 ~tM ~ [42] 
Fatty acylcarnitine 85.8/aM ~ [42] 
Total carnitine 977.9 gM ~ [42] 
Dog myocytes (control) 
Sarcolemma Fatty acylcarnitine 70 gM ~ [43] 
Mitochondria Fatty acylcarnitine 467 gM a [43] 
Cytosol Fatty acylcarnitine 427 gM ~ [43] 
Dog myocytes (hypoxia) 
Sarcolemma Fatty acylcarnitine 6967 ~M a [43] 
Mitochondria Fatty acylcarnitine 773 gM ~ [43] 
Cytosol Fatty acylcarnitine 357 gM a [43] 
These values are only approximate, since they were originally published in units not directly convertible into IS units (e.g. nmol per 10 9 cells). 
b Acid-soluble carnitine refers to free plus short-chain acid esterified carnitine. 
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Fig. 2. A schematic view of the fatty acid import mechanism in mi- 
tochondria. CPT, creatine palmitoyltransferase. CAT, carnitine-acyl- 
carnitine translocase. 
[25]. Coenzyme A is important in a variety of metabolic path- 
ways: as an acetyl carrier, in the synthesis of acetylcholine, 
ketone bodies and fatty acids, and as a substrate for enzymes 
of the Krebs cycle. On the contrary, the carnitine pool is a 
metabolic dead end. Also, carnitine would be available in 
larger amounts than coenzyme A (Table 1). Thus the rela- 
tively unreactive acylcarnitines would be stored as a reservoir 
of activated acyl groups, which would be transferred to coen- 
zyme A according to the needs of the cell [25,26]. This would 
be correct from the point of view of chemical reactivity, con- 
sidering that the thioester bond of coenzyme A derivatives i
far less stable than the O-ester group of palmitoylcarnitine. 
However, as was pointed out in the former section, palmitoyl- 
CoA is virtually inert with respect o bilayer destabilization, 
while palmitoylcarnitine is a powerful surfactant, so that stor- 
age of free palmitoylcarnitine b yond a certain limit (that can 
be estimated at around the critical micellar concentration, 
,-0 10 -~ M) is not compatible with the maintenance of a tight 
membrane. Thus our studies on the relative membrane lyric 
properties of acyl-CoAs and acylcarnitines [11] are hardly 
compatible with the idea of a significant pool of acylcarni- 
tines. In fact, although the overall carnitine concentration i
the cell is rather high, most of it is in the non-esterified form 
(Table 1). Apparent Km values for palmitoylcarnitine in the 
carnitine palmitoyltransferases have been estimated at 1- 
5 × 10 -5 M [27,28]. These are just above the critical micellar 
concentration of palmitoylcarnitine, so that these enzymes 
would prevent the build-up of dangerous concentrations of 
that metabolite, against he concept of large pools of acylcar- 
nitine in membranes. It should also be noted, in this respect, 
that a significant fraction of acylcarnitine may exist in the cell 
in protein-bound form, so that it would be relatively harmless 
to membranes. 
Genetic deficiencies have been described [29] for each of the 
three proteins involved in fatty acid import, namely carnitine 
palmitoyltransferase I, carnitine-acylcarnitine translocase and 
carnitine palmitoyltransferase II. Of all three, the neonatal 
form of deficiency of carnitine palmitoyltransferase II is par- 
ticularly lethal, the infants dying of cardiac arrest at the age of 
3-5 days. A possible pathogenic factor in the latter disease 
could be the accumulation of palmitoylcarnitine in the mito- 
chondrial membrane producing leakage, i.e. mitochondrial 
uncoupling, and subsequent impairment of all the energy-re- 
quiring processes in the cell. 
4. Palmitoylcarnitine and myocardial ischemia 
Palmitoylcarnitine may be involved in pathological proc- 
esses unrelated to the machinery of mitochondrial fatty acid 
import that we have just reviewed. In particular, increased 
levels of acylcarnitines have been implicated in the pathology 
of cardiac ischemia for the last two decades. Wood et al. [30] 
demonstrated that palmitoylcarnitine was a potent inhibitor 
of isolated cardiac Na,K-ATPase, and, as mentioned above, 
Adams et al. [7] demonstrated that the palmitoylcarnitine ef-
fect on sarcolemmal nd sarcoplasmic reticulum membranes 
was due to the surfactant properties of that amphiphile. These 
observations have become more relevant in the light of recent 
results: palmitoylcarnitine concentrations in the heart sarco- 
lemma (plasma membrane) have been reported to increase in 
cells subjected to hypoxia for 10 min (Table 1) [31,40,43]. 
More recently, Wu and Corr [32] have shown that palmitoyl- 
carnitine modifies sodium currents and elicits a transient in- 
ward current in isolated rabbit ventricular cells. According to 
the latter authors, the primary effect of the amphiphile would 
be to induce a Na + inward current, which would in turn elicit 
an increase in intracellular Ca 2+ via Na÷/Ca 2+ exchanger, 
leading to the development of delayed after-depolarizations 
and triggered activity. Wu and Corr [32] pointed out that 
similar 'Na+-channel openings' have been observed with lyso- 
phosphatidyl-choline [33]. The data by Requero et al. [11] on 
vesicle leakage induced by palmitoylcarnitine are in agreement 
with those observations and may explain the role of fatty 
acylcarnitines in acute myocardial ischemia. 
The amphipathic properties of palmitoylcarnitine are used 
by Pappano and co-workers to explain in a different way at 
least some of the pathologic effects of palmitoylcarnitine and 
particularly the inhibition of the Na,K-ATPase. According to 
them, palmitoylcarnitine incorporates into the membranes 
and its insertion leads to a reduction of the surface negative 
charge [34]. In turn, reduction of negative charge in the en- 
vironment of Na,K-ATPase molecules would mimic the hy- 
perpolarization-induced reduction of Na efflux and Na/K cur- 
rent seen in squid giant axon [35]. In favor of the surface 
charge hypothesis is the fact that it allows for effects at low 
amphiphile concentrations, not requiring membrane disrup- 
tion. A related similar effect of palmitoylcarnitine at low con- 
centrations i the increased Ca ~+ release from skeletal muscle 
sarcoplasmic reticulum [36]. The mechanism appears in this 
case to be one of direct interaction with the channel (ryano- 
dine receptor), involving particularly the hydrocarbon chain 
moiety of the amphiphile, since long-chain coenzyme A deriv- 
atives appear to have a similar effect. Interestingly, carnitine 
and its short-chain esters appear to have a protective ffect in 
perfused hearts subjected to ischemia or to oxidative stress 
[37]. The mechanisms involved are obscure, but the protective 
effects do not appear to be directly related to fatty acid me- 
tabolism. 
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